{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:06:21Z","timestamp":1779379581678,"version":"3.53.1"},"reference-count":146,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Cystic fibrosis (CF) lung disease is characterized by chronic infection and progressive airway damage, driven by interactions between epithelial dysfunction, immune dysregulation, and microbial adaptation. Defective cystic fibrosis transmembrane conductance regulator (CFTR) function disrupts airway hydration and mucociliary clearance, creating a microenvironment that facilitates infection, particularly with Pseudomonas aeruginosa (P. aeruginosa). Within this environment, P. aeruginosa undergoes adaptive changes, including biofilm formation and metabolic reprogramming, which support long-term survival in the airway. Concurrently, host immune responses become dysregulated, with ineffective bacterial clearance and sustained neutrophil-dominated inflammation contributing to tissue injury. These processes establish a self-reinforcing cycle that drives disease progression. Importantly, early infection represents a critical therapeutic window during which bacterial populations remain more amenable to eradication before irreversible airway remodeling occurs. Delayed intervention promotes transition to a more treatment-refractory state and accelerates disease progression. Despite the clinical benefits of CFTR modulators, airway damage and established infections often remain. The relative contributions and interactions of epithelial dysfunction, immune dysregulation, and bacterial adaptation in sustaining chronic infection remain incompletely defined, representing a key knowledge gap. In this context, this review aims to integrate current evidence on host\u2013pathogen co-adaptation in CF lung disease, with a particular focus on P. aeruginosa, and highlight emerging therapeutic strategies.<\/jats:p>","DOI":"10.3390\/pathogens15050557","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:02:27Z","timestamp":1779375747000},"page":"557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Host\u2013Pathogen Interactions in Cystic Fibrosis Lung Disease: Adaptation, Persistence, and Clinical Implications of Pseudomonas aeruginosa"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-7855","authenticated-orcid":false,"given":"Burcu","family":"Capraz Yavuz","sequence":"first","affiliation":[{"name":"Pediatric Pulmonology Department, Ankara Bilkent City Hospital, 06800 Ankara, T\u00fcrkiye"},{"name":"Department of Translational Medicine, Institute of Health Sciences, Ankara Yildirim Beyazit University, 06800 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/bmj.39391.713229.AD","article-title":"Cystic fibrosis","volume":"335","author":"Davies","year":"2007","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/all.16318","article-title":"The epithelial barrier theory and its associated diseases","volume":"79","author":"Sun","year":"2024","journal-title":"Allergy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21465","DOI":"10.1038\/srep21465","article-title":"Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections","volume":"6","author":"Cigana","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1802456","DOI":"10.1183\/13993003.02456-2018","article-title":"Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa","volume":"55","author":"Cigana","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jarzynka, S., Makarewicz, O., Weiss, D., Minkiewicz-Zochniak, A., Iwa\u0144ska, A., Skorupa, W., Padzik, M., Augustynowicz-Kope\u0107, E., and Ol\u0119dzka, G. (2023). The Impact of Pseudomonas aeruginosa Infection in Adult Cystic Fibrosis Patients-A Single Polish Centre Study. Pathogens, 12.","DOI":"10.3390\/pathogens12121440"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40101-021-00269-7","article-title":"The determinants of survival among adults with cystic fibrosis-a cohort study","volume":"40","author":"John","year":"2021","journal-title":"J. Physiol. Anthropol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcf.2025.08.019","article-title":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry","volume":"24","author":"Pollak","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.chom.2025.07.009","article-title":"Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation","volume":"33","author":"Durfey","year":"2025","journal-title":"Cell Host Microbe"},{"key":"ref_12","unstructured":"Cystic Fibrosis Foundation (2026, May 01). Cystic Fibrosis Foundation Patient Registry 2024 Annual Data Report. Available online: https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Terlizzi, V., Timitilli, E., Fiumara, M.S., Dolce, D., Campana, S., and Chiappini, E. (Paediatr. Respir. Rev., 2026). Detection of Pseudomonas aeruginosa in cystic fibrosis after initiation of CFTR modulators: A systematic review, Paediatr. Respir. Rev., in press.","DOI":"10.1016\/j.prrv.2026.01.004"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annalsats\/aaoaf056","article-title":"Does it matter how cystic fibrosis transmembrane conductance regulator modulators reduce inflammation in cystic fibrosis?","volume":"23","author":"Flume","year":"2026","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Pescaru, C.C., Cri\u0219an, A.F., Mari\u021bescu, A., C\u0103runta, V., Marc, M., Dumitrache-Rujinski, \u0218., Laitin, S., and Oancea, C. (2025). Effects of CFTR Modulators on Pseudomonas aeruginosa Infections in Cystic Fibrosis. Infect. Dis. Rep., 17.","DOI":"10.3390\/idr17040080"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jleuko\/qiad139","article-title":"Aberrant immune programming in neutrophils in cystic fibrosis","volume":"115","author":"Hu","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e71555","DOI":"10.1002\/ppul.71555","article-title":"Hypochloremic Hypokalemic Metabolic Alkalosis as a Manifestation of CFTR-Related Disorder","volume":"61","author":"Dogru","year":"2026","journal-title":"Pediatr. Pulmonol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","article-title":"Evidence for airway surface dehydration as the initiating event in CF airway disease","volume":"261","author":"Boucher","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ehre, C., Mall, M.A., and McElvaney, G.N. (J. Cyst. Fibros., 2026). Mucus and inflammation in the HEMT Era: Persistent barriers to complete airway normalization in cystic fibrosis, J. Cyst. Fibros., in press.","DOI":"10.1016\/j.jcf.2026.03.010"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s42003-025-07877-4","article-title":"ENaC is a host susceptibility factor to bacterial infections in cystic fibrosis context","volume":"8","author":"Durand","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bal\u00e1zs, A., and Mall, M.A. (2018). Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01112"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Najm, M., Martignetti, L., Cornet, M., Kelly-Aubert, M., Sermet, I., Calzone, L., and Stoven, V. (2024). From CFTR to a CF signalling network: A systems biology approach to study Cystic Fibrosis. BMC Genom., 25.","DOI":"10.1186\/s12864-024-10752-x"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1038\/ncomms7201","article-title":"Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis","volume":"6","author":"Rimessi","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2415345122","DOI":"10.1073\/pnas.2415345122","article-title":"Epigenetic cellular memory in Pseudomonas aeruginosa generates phenotypic variation in response to host environments","volume":"122","author":"Vatareck","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pankonien, I., Quaresma, M.C., Rodrigues, C.S., and Amaral, M.D. (2022). CFTR, Cell Junctions and the Cytoskeleton. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052688"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19797","DOI":"10.1074\/jbc.273.31.19797","article-title":"An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton","volume":"273","author":"Short","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00424-014-1474-6","article-title":"Pseudomonas aeruginosa reduces the expression of CFTR via post-translational modification of NHERF1","volume":"466","author":"Rubino","year":"2014","journal-title":"Pflugers Arch."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm1603","article-title":"Identification of a key pathway required for the sterile inflammatory response triggered by dying cells","volume":"13","author":"Chen","year":"2007","journal-title":"Nat. Med."},{"key":"ref_30","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Rodrigues, C.S., Canto, M., Torres, R., Railean, V., Ramalho, S.S., Farinha, C.M., Pankonien, I., and Amaral, M.D. (2025). CFTR ion transport deficiency primes the epithelium for partial epithelial-mesenchymal transition in cystic fibrosis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1655479"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1900716","DOI":"10.1183\/13993003.00716-2019","article-title":"IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease","volume":"57","author":"Hagner","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.201206-1150OC","article-title":"A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection","volume":"187","author":"Tiringer","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mulcahy, E.M., Hudson, J.B., Beggs, S.A., Reid, D.W., Roddam, L.F., and Cooley, M.A. (2015). High peripheral blood th17 percent associated with poor lung function in cystic fibrosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120912"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104926","DOI":"10.1016\/j.cellimm.2025.104926","article-title":"IL-17 family members exert an autocrine pro-inflammatory loop in CF respiratory epithelial cells ex vivo","volume":"409\u2013410","author":"Allegretta","year":"2025","journal-title":"Cell Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nickerson, R., Thornton, C.S., Johnston, B., Lee, A.H.Y., and Cheng, Z. (2024). Pseudomonas aeruginosa in chronic lung disease: Untangling the dysregulated host immune response. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1405376"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhang, D., Zhang, W., Hu, P., and Zhang, W. (2025). Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: Mechanisms, clinical trials, and therapeutic prospects. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1656316"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e00471-25","DOI":"10.1128\/jb.00471-25","article-title":"Contribution of two-component regulatory systems to the acute-to-chronic infection transition of Pseudomonas aeruginosa in cystic fibrosis","volume":"208","author":"Ares","year":"2026","journal-title":"J. Bacteriol."},{"key":"ref_39","first-page":"S82","article-title":"Infection and Inflammation in the Cystic fibrosis (CF) airway","volume":"60","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1172\/JCI125669","article-title":"IL-1\u03b2 dominates the promucin secretory cytokine profile in cystic fibrosis","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wellems, D., Hu, Y., Jennings, S., and Wang, G. (2023). Loss of CFTR function in macrophages alters the cell transcriptional program and delays lung resolution of inflammation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1242381"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ribeiro, C.M.P., Higgs, M.G., Muhlebach, M.S., Wolfgang, M.C., Borgatti, M., Lampronti, I., and Cabrini, G. (2023). Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24055010"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"De, M., Serpa, G., Zuiker, E., Hisert, K.B., Liles, W.C., Manicone, A.M., Hemann, E.A., and Long, M.E. (2024). MEK1\/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection. Front. Cell Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1275940"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hwang, W., Yong, J.H., Lenneman, B.R., and Yonker, L.M. (2026). Phage-Based Approaches to Chronic Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis. Antibiotics, 15.","DOI":"10.3390\/antibiotics15020125"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.immuni.2022.04.001","article-title":"Tissue remodeling by an opportunistic pathogen triggers allergic inflammation","volume":"55","author":"Agaronyan","year":"2022","journal-title":"Immunity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.it.2022.05.002","article-title":"Pseudomonas aeruginosa: A pathogen making itself at home","volume":"43","author":"Lloyd","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chen, J., Kinter, M., Shank, S., Cotton, C., Kelley, T.J., and Ziady, A.G. (2008). Dysfunction of Nrf-2 in CF epithelia leads to excess intracellular H2O2 and inflammatory cytokine production. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003367"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"G839","DOI":"10.1152\/ajpgi.00582.2005","article-title":"Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis","volume":"292","author":"Beharry","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1165\/rcmb.2004-0117OC","article-title":"Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C","volume":"31","author":"White","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Holbrook","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, P., Wang, J., Miao, J., and Zhu, P. (2025). The dual role of tissue regulatory T cells in tissue repair: Return to homeostasis or fibrosis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1560578"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2021.05.001","article-title":"Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis","volume":"20","author":"Beckert","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcf.2020.10.008","article-title":"Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"20","author":"Jackson","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Borisova, D., Paunova-Krasteva, T., Strateva, T., and Stoitsova, S. (2025). Biofilm Formation of Pseudomonas aeruginosa in Cystic Fibrosis: Mechanisms of Persistence, Adaptation, and Pathogenesis. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071527"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1183\/09031936.00043108","article-title":"Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis","volume":"33","author":"Douglas","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S2213-2600(15)00228-3","article-title":"The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: A cross-sectional analysis","volume":"3","author":"Kidd","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"fuaf018","DOI":"10.1093\/femsre\/fuaf018","article-title":"Harnessing hypoxia: Bacterial adaptation and chronic infection in cystic fibrosis","volume":"49","author":"Carey","year":"2025","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Reuven, A.D., Katzenell, S., Mwaura, B.W., and Bliska, J.B. (2025). ExoS effector in Pseudomonas aeruginosa Hyperactive Type III secretion system mutant promotes enhanced Plasma Membrane Rupture in Neutrophils. PLoS Pathog., 21.","DOI":"10.1371\/journal.ppat.1013021"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Scoffone, V.C., Trespidi, G., Chiarelli, L.R., Barbieri, G., and Buroni, S. (2019). Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081838"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2012.07.008","article-title":"Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa","volume":"12","author":"Schelstraete","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00431-024-05905-9","article-title":"Antibiotic treatment of bacterial lung infections in cystic fibrosis","volume":"184","author":"Taccetti","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/infdis\/jiaf527","article-title":"Culture and Adaptation of Pseudomonas aeruginosa During Early Infection in Children With Cystic Fibrosis","volume":"233","author":"Mitra","year":"2026","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41467-019-08504-7","article-title":"Evolutionary highways to persistent bacterial infection","volume":"10","author":"Bartell","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1900840","DOI":"10.1002\/advs.201900840","article-title":"Sublethal Levels of Antibiotics Promote Bacterial Persistence in Epithelial Cells","volume":"7","author":"Liu","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sultan, M., Arya, R., and Kim, K.K. (2021). Roles of Two-Component Systems in Pseudomonas aeruginosa Virulence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212152"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bjarnsholt, T., Jensen, P., Jakobsen, T.H., Phipps, R., Nielsen, A.K., Rybtke, M.T., Tolker-Nielsen, T., Givskov, M., H\u00f8iby, N., and Ciofu, O. (2010). Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010115"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41579-025-01193-8","article-title":"Pseudomonas aeruginosa: Ecology, evolution, pathogenesis and antimicrobial susceptibility","volume":"23","author":"Letizia","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11741","DOI":"10.1038\/s41598-023-39005-9","article-title":"Phenotypic and genotypic characteristics of Pseudomonas aeruginosa isolated from cystic fibrosis patients with chronic infections","volume":"13","author":"Trafny","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"108782","DOI":"10.1016\/j.celrep.2021.108782","article-title":"Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies","volume":"34","author":"Jennings","year":"2021","journal-title":"Cell Rep."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Thi, M.T.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228671"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ren, L., Yuan, Y., Farea, K., Feng, X., He, J., Liu, Y., and Zheng, B. (2025). The adaptability of Pseudomonas aeruginosa biofilm in oxygen-limited environments. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1655335"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood.2021014699","article-title":"Neutrophil dysfunction in the pathogenesis of cystic fibrosis","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/1751-7915.14487","article-title":"Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications","volume":"17","author":"Wu","year":"2024","journal-title":"Microb. Biotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.bioflm.2022.100089","article-title":"Interplay between biofilm microenvironment and pathogenicity of Pseudomonas aeruginosa in cystic fibrosis lung chronic infection","volume":"4","author":"Guillaume","year":"2022","journal-title":"Biofilm"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., Marzouk, E., Edrees, H.M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., and Jaber, M. (2026). Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches. Microorganisms, 14.","DOI":"10.3390\/microorganisms14010109"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Reyes Ruiz, L.M., Williams, C.L., and Tamayo, R. (2020). Enhancing bacterial survival through phenotypic heterogeneity. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008439"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hirsch, M.J., Hughes, E.M., Easter, M.M., Bollenbecker, S.E., Howze Iv, P.H., Birket, S.E., Barnes, J.W., Kiedrowski, M.R., and Krick, S. (2023). A novel in vitro model to study prolonged Pseudomonas aeruginosa infection in the cystic fibrosis bronchial epithelium. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0288002"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2113723119","DOI":"10.1073\/pnas.2113723119","article-title":"The structural role of bacterial eDNA in the formation of biofilm streamers","volume":"119","author":"Secchi","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jpha.2022.12.003","article-title":"Neutrophil elastase: From mechanisms to therapeutic potential","volume":"13","author":"Zeng","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-016-0449-x","article-title":"Neutrophil elastase cleaves epithelial cadherin in acutely injured lung epithelium","volume":"17","author":"Boxio","year":"2016","journal-title":"Respir. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Voynow, J.A., and Shinbashi, M. (2021). Neutrophil Elastase and Chronic Lung Disease. Biomolecules, 11.","DOI":"10.3390\/biom11081065"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2500081","DOI":"10.1183\/13993003.00081-2025","article-title":"Neutrophil-derived biomarkers in bronchiectasis: Identifying a common therapeutic target","volume":"66","author":"Chalmers","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"230015","DOI":"10.1183\/16000617.0015-2023","article-title":"Basic, translational and clinical aspects of bronchiectasis in adults","volume":"32","author":"Chalmers","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Oriano, M., Amati, F., Gramegna, A., De Soyza, A., Mantero, M., Sibila, O., Chotirmall, S.H., Voza, A., Marchisio, P., and Blasi, F. (2021). Protease-Antiprotease Imbalance in Bronchiectasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115996"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ghigo, A., Prono, G., Riccardi, E., and De Rose, V. (2021). Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041952"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4049\/jimmunol.1201404","article-title":"Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells","volume":"190","author":"Mayer","year":"2013","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yu, C., and Kotsimbos, T. (2023). Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044052"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ccm.2022.06.004","article-title":"Update on Innate and Adaptive Immunity in Cystic Fibrosis","volume":"43","author":"Bruscia","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e17553","DOI":"10.1016\/j.heliyon.2023.e17553","article-title":"Role of innate immunity and systemic inflammation in cystic fibrosis disease progression","volume":"9","author":"Purushothaman","year":"2023","journal-title":"Heliyon"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1128\/AAC.48.5.1676-1680.2004","article-title":"Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"48","author":"Vogne","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/thorax.55.9.795","article-title":"Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease","volume":"55","author":"Thomas","year":"2000","journal-title":"Thorax"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10241","DOI":"10.1038\/srep10241","article-title":"Lung microbiota across age and disease stage in cystic fibrosis","volume":"5","author":"Coburn","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Qu, J., Yin, L., Qin, S., Sun, X., Gong, X., Li, S., Pan, X., Jin, Y., Cheng, Z., and Jin, S. (2025). Identification of the Pseudomonas aeruginosa AgtR-CspC-RsaL pathway that controls Las quorum sensing in response to metabolic perturbation and Staphylococcus aureus. PLoS Pathog., 21.","DOI":"10.1371\/journal.ppat.1013054"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1164\/rccm.202312-2326LE","article-title":"Chronicity Counts: The Impact of Pseudomonas aeruginosa, Staphylococcus aureus, and Coinfection in Cystic Fibrosis","volume":"210","author":"Mossop","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2503430","DOI":"10.1080\/21505594.2025.2503430","article-title":"Pathogenicity and virulence of Pseudomonas aeruginosa: Recent advances and under-investigated topics","volume":"16","author":"Swain","year":"2025","journal-title":"Virulence"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"200011","DOI":"10.1183\/16000617.0011-2020","article-title":"Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis","volume":"29","author":"Keown","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jcf.2022.07.009","article-title":"An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway samples","volume":"22","author":"Hughes","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1038\/s41598-021-85592-w","article-title":"An observational study of anaerobic bacteria in cystic fibrosis lung using culture dependant and independent approaches","volume":"11","author":"Lamoureux","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People with Cystic Fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcf.2026.02.010","article-title":"Cystic fibrosis year in review 2025","volume":"25","author":"Pallenberg","year":"2026","journal-title":"J. Cyst. Fibros"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"240068","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: When to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_106","first-page":"Cd004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"6","author":"Smith","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"220154","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Taccetti, G., Francalanci, M., Pizzamiglio, G., Messore, B., Carnovale, V., Cimino, G., and Cipolli, M. (2021). Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10030338"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10096-015-2347-4","article-title":"Azithromycin use in patients with cystic fibrosis","volume":"34","author":"Principi","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled trial","volume":"8","author":"Hewer","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: Past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Buruian\u0103, G., Sima, C.M., Anton-P\u0103duraru, D.-T., B\u0103descu, A.C., Lunc\u0103, C., Duhaniuc, A., and Dorneanu, O.S. (2025). Airway Microbiome in Children with Cystic Fibrosis: A Review of Microbial Shifts and Therapeutic Impacts. Medicina, 61.","DOI":"10.3390\/medicina61091605"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jac\/dkae126","article-title":"In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain","volume":"79","author":"Oliver","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1128\/AAC.01046-16","article-title":"Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe","volume":"60","author":"Mustafa","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e01541-19","DOI":"10.1128\/AAC.01541-19","article-title":"Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics","volume":"64","author":"Ekkelenkamp","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12941-021-00415-0","article-title":"Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"20","author":"Lasko","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"dlab126","DOI":"10.1093\/jacamr\/dlab126","article-title":"Antimicrobial activity of ceftazidime\/avibactam, ceftolozane\/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_119","first-page":"537.e7","article-title":"Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"29","author":"Penev","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.pathol.2023.03.009","article-title":"Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia","volume":"55","author":"Kostoulias","year":"2023","journal-title":"Pathology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e0443722","DOI":"10.1128\/spectrum.04437-22","article-title":"Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients","volume":"11","author":"Marner","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/49.2.403","article-title":"In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany","volume":"49","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1128\/JCM.42.12.5842-5845.2004","article-title":"Azithromycin retards Pseudomonas aeruginosa biofilm formation","volume":"42","author":"Gillis","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Martin, I., Waters, V., and Grasemann, H. (2021). Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042155"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Baral, P.K., Dummer, J., Pletzer, D., and Das, S.C. (2026). Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosa. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18020162"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Gonzaga, Z.J.C., Merakou, C., DiGiandomenico, A., Priebe, G.P., and Rehm, B.H.A. (2021). A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection. Vaccines, 9.","DOI":"10.3390\/vaccines9070803"},{"key":"ref_130","first-page":"345","article-title":"Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine","volume":"98","author":"Cryz","year":"1997","journal-title":"Behring Inst. Mitt."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Bianconi, I., Alcal\u00e1-Franco, B., Scarselli, M., Dalsass, M., Buccato, S., Colaprico, A., Marchi, S., Masignani, V., and Bragonzi, A. (2018). Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03021"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1099\/jmm.0.46658-0","article-title":"Immunization with 3-oxododecanoyl-L-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection","volume":"55","author":"Miyairi","year":"2006","journal-title":"J. Med. Microbiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/1348-0421.13156","article-title":"Biofilm-derived membrane vesicles exhibit potent immunomodulatory activity in Pseudomonas aeruginosa PAO1","volume":"68","author":"Takahara","year":"2024","journal-title":"Microbiol. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Fantone, K.M., Gokanapudi, N., and Rada, B. (2025). Neutrophil extracellular traps and interleukin-1\u03b2 in cystic fibrosis lung disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1595994"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42269-023-01005-0","article-title":"NLRP3 inflammasome as a novel target for cystic fibrosis treatment","volume":"47","author":"Atalay","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_136","first-page":"151","article-title":"Specialized pro-resolving mediators\u2019 biosynthesis by cystic fibrosis airway epithelial cells and their impact on mucociliary clearance","volume":"8","author":"Briottet","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s40262-025-01550-z","article-title":"A Phase IIa, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics\/Pharmacodynamics of Brensocatib in Adults with Cystic Fibrosis","volume":"64","author":"Konstan","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Rossitto, M., Fiscarelli, E.V., and Rosati, P. (2018). Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.00775"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1038\/s41467-025-60598-4","article-title":"Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: A randomized first-in-human trial","volume":"16","author":"Weiner","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"104372","DOI":"10.1016\/j.isci.2022.104372","article-title":"Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates","volume":"25","author":"Nordstrom","year":"2022","journal-title":"iScience"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Saluzzo, F., Riberi, L., Messore, B., Lor\u00e9, N.I., Esposito, I., Bignamini, E., and De Rose, V. (2022). CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells, 11.","DOI":"10.3390\/cells11071243"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e0023025","DOI":"10.1128\/iai.00230-25","article-title":"A chronic Pseudomonas aeruginosa mouse lung infection modeling the mucus obstruction, lung function, and inflammation of human cystic fibrosis","volume":"93","author":"Vaillancourt","year":"2025","journal-title":"Infect. Immun."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Rodgers, A.M., Lindsay, J., Monahan, A., Dubois, A.V., Faniyi, A.A., Plant, B.J., Mall, M.A., Ekkelenkamp, M.B., Elborn, S., and Ingram, R.J. (2023). Biologically Relevant Murine Models of Chronic Pseudomonas aeruginosa Respiratory Infection. Pathogens, 12.","DOI":"10.20944\/preprints202306.0293.v1"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-018-0750-y","article-title":"Airway disease phenotypes in animal models of cystic fibrosis","volume":"19","author":"McCarron","year":"2018","journal-title":"Respir. Res."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/5\/557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:19:29Z","timestamp":1779376769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/5\/557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":146,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["pathogens15050557"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15050557","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}